NCT01345201View on ClinicalTrials.gov

A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Solid Tumors
Interventions
BIOLOGICAL

OMP-18R5

IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.

Trial Locations (3)

48109

University of Michigan Health System, Ann Arbor

78229

South Texas Accelerated Research Therapeutics, San Antonio

90404

UCLA Santa Monica Hematology-Oncology, Santa Monica

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY